Xentria, Inc.
Xentria is a private Chicago-based biopharmaceutical company developing therapeutics for unmet clinical needs. Its lead asset, XTMAB-16, is in clinical development for pulmonary sarcoidosis, while its Xturnpoint venture studio partners with academic institutions to advance early-stage therapeutic programs.
- Company typePrivate
- Founded2020
- HeadquartersChicago, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What Xentria, Inc. does
Xentria, Inc. is a private biopharmaceutical company headquartered in Chicago, Illinois, founded in 2020. The company develops therapeutics for unmet clinical needs, with its lead asset XTMAB-16 — a chimeric human-murine anti-TNF monoclonal antibody designed to suppress inflammatory pathways and granuloma formation — currently in clinical development for pulmonary sarcoidosis, a rare inflammatory disease affecting fewer than 200,000 US patients. XTMAB-16 has received Orphan Drug Designation from both the FDA (December 2020) and the EMA (November 2023), and Phase 1b/2a first-in-patient results presented at ATS 2026 demonstrated a favorable safety and tolerability profile, supporting selection of a 4mg/kg Q4W dose for continued evaluation. The company also holds an exclusive license from NYU Langone Health for a disease-modifying cardiovascular therapy and, through a partnership with Inotiv, achieved an FDA regulatory submission for biosimilar insulin aspart in April 2026, one year ahead of schedule.
Xentria operates a dual business model combining internal drug development with a venture studio called Xturnpoint, which was launched in May 2025 with $100M in deployable capital. Xturnpoint engages academic institutions and biotech researchers to identify and co-develop early-stage therapeutic programs, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry at the preclinical and pre-IND stages. In 2025, Xturnpoint reviewed over 100 academic opportunities spanning institutions, scientific domains, and stages from early discovery through Phase II. The company describes its team as small by design, enabling focused program attention and continuity from opportunity review through program leadership.
The company's revenue mechanics are partnership-based: licensing royalties, development milestone payments, and equity stakes in co-developed programs. Customer segments are academic medical centers and research institutions, with named collaborators including NYU Langone Health, East Carolina University's Sarcoidosis Center of Excellence, and a broader portfolio of academic teams engaged through Xturnpoint. Go-to-market is sales-led and direct, relying on bilateral co-development agreements, exclusive licensing, and conference presence at events such as ATS and WASOG/AASOG rather than traditional commercial distribution. No public revenue or headcount figure is disclosed.
Xentria, Inc. firmographics
Firmographics- Name
- Xentria, Inc.
- Legal name
- Xentria, Inc.
- Website
- https://xentria.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Short description
- Xentria is a private Chicago-based biopharmaceutical company developing therapeutics for unmet clinical needs. Its lead asset, XTMAB-16, is in clinical development for pulmonary sarcoidosis, while its Xturnpoint venture studio partners with academic institutions to advance early-stage therapeutic programs.
- Ownership category
- akta.pro rank
Xentria, Inc. industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where Xentria, Inc. is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Xentria, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Co-development partnerships and venture studio model: Xturnpoint invests capital ($100M to deploy) in early-stage academic therapeutic programs. Revenue is generated through partnership agreements, milestone payments, and equity stakes in developed programs. Shared-incentive models align both sides around clearly defined milestones and expectations.
- Licensing and development partnerships: Exclusive licensing agreements with academic institutions (e.g., NYU Langone Health) to advance disease-modifying cardiovascular therapies globally. Revenue from development milestones and commercialization rights.
- Biosimilar development: Partnership with Inotiv achieving FDA regulatory submission for biosimilar insulin aspart, demonstrating milestone-based development revenue.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Xentria, Inc. product offering
Product offeringCore offering
Xentria is a biopharmaceutical company that develops biologic therapeutics for unmet clinical needs, with its lead asset XTMAB-16, an anti-TNF monoclonal antibody in clinical development for pulmonary sarcoidosis. The company also operates Xturnpoint, a venture studio with $100M in deployable capital that partners with academic researchers to advance early-stage therapeutic programs from preclinical through lead-optimization stages.
Product overview
Xentria is a biotech company offering a dual approach to life-sciences partnerships: (1) XTMAB-16, their lead investigational biologic therapy in clinical development for pulmonary sarcoidosis, and (2) Xturnpoint, a venture studio that identifies and supports early-stage academic therapeutic programs through preclinical development and IND-enabling studies.
Differentiator
Problem solved
Functional benefit
Brands
- Xturnpoint: A venture studio launched by Xentria in 2025 to fuel early-stage therapeutic innovation, with $100M to deploy for identifying and supporting academic innovation programs.
Products and services
- XTMAB-16 Novel chimeric human-murine anti-TNF monoclonal antibody being developed as an investigational biologic product for the treatment of pulmonary sarcoidosis with or without extra pulmonary involvement. Designed to suppress inflammatory pathways and granuloma formation by blocking TNF-alpha.
- Xturnpoint Venture studio initiative launched in 2025 with $100M to deploy, focused on early-stage therapeutic innovation. Partners with academic institutions and researchers to advance discoveries from preclinical through lead optimization stages.
- Biosimilar Insulin Aspart (Co-development with Inotiv) Co-developed biosimilar insulin aspart product with Inotiv, achieving FDA regulatory submission one year ahead of schedule. The biosimilar was developed through partnership with Inotiv providing contract research services supporting regulatory submissions.
Quantifiable outcome
- XTMAB-16 demonstrated favorable safety and tolerability profile in pulmonary sarcoidosis patients with no unexpected TNF-inhibitor class effects
- +2 more outcomes
Companies that use Xentria, Inc.
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Xentria, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Xentria, Inc. partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- InotivmajorStrategic partnership resulting in FDA regulatory submission for biosimilar insulin aspart achieved one year ahead of schedule. Inotiv provides contract research services supporting regulatory submissions and development programs.
- XturnpointcoreXturnpoint is Xentria's venture studio initiative launched in 2025 with $100M to deploy. It identifies early-stage therapeutic innovation opportunities across academic institutions, providing capital plus hands-on strategic guidance to bridge the funding gap between academia and industry in preclinical and pre-IND research stages.
- Academic Institutions (Portfolio)coreXturnpoint engaged with over 100 academic teams across institutions in 2025, reviewing opportunities spanning early discovery through Phase II. Partnerships came through tech transfer offices, consulting groups, and scientific collaborators. Focus remains on preclinical and lead-optimization stages.
- NYU Langone HealthcoreExclusive licensing agreement to advance a disease-modifying cardiovascular therapy globally. Dr. David S. Park, Associate Professor of Medicine, noted Xentria's comprehensive approach from concept through preclinical testing, regulatory approvals, and clinical trials as setting it apart from other interested groups.
- East Carolina University (ECU) - Sarcoidosis Center of ExcellencecoreDr. Ogugua N. Obi, Director of the Sarcoidosis Center of Excellence at ECU, presented first-in-patient study results for XTMAB-16 in sarcoidosis at ATS 2026. ECU serves as a key clinical collaborator for the Phase 1b/2a MAD study.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Xentria, Inc. competitors and assessment
Company assessmentDirect peers
- PureTech Health: Clinical-stage biotherapeutics company that builds on academic research through founded programs, closely aligned with Xentria's venture studio strategy of advancing preclinical academic discoveries.
- Roivant Sciences: Clinical-stage biopharmaceutical company that operates a 'Vant' model of focused subsidiaries, sharing Xentria's venture-studio approach to developing therapeutic assets through dedicated operating units.
- aTyr Pharma: Clinical-stage biotherapeutics company developing immunology-focused protein therapeutics for rare inflammatory conditions, sharing Xentria's biologics platform and rare disease focus.
- BridgeBio Pharma: Commercial-stage biopharma focused on genetic and rare diseases using a hub-and-spoke co-development model with academic researchers, mirroring Xentria's academic partnership approach.
- Scholar Rock: Clinical-stage biopharmaceutical company developing biologics that target growth factor signaling for rare diseases, similar to Xentria's antibody-based approach in orphan indications.
- Travere Therapeutics: Biopharmaceutical company focused on rare diseases with a partnership-driven development approach, comparable to Xentria's co-development model and orphan drug strategy.
- Pliant Therapeutics: Clinical-stage biopharmaceutical company developing biologics for serious fibrotic diseases, comparable in scale and stage to Xentria with a similar small-team, focused-program structure.
Broad incumbents
- Janssen Pharmaceuticals: Manufacturer of Remicade (infliximab) and Stelara, a major player in the anti-TNF and immunology biologics market relevant to Xentria's TNF-α pathway approach.
- Amgen: Manufacturer of Enbrel (etanercept), a foundational anti-TNF biologic, representing an established incumbent whose off-label use in sarcoidosis affects XTMAB-16's competitive landscape.
- AbbVie: Manufacturer of Humira (adalimumab), the leading anti-TNF-α biologic, directly relevant as the incumbent benchmark in the anti-TNF space where XTMAB-16 competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Xentria, Inc. social profiles
Digital presenceXentria, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xentria, Inc. leadership team
Management profileNumber of profiles
Profiles6 records
Xentria, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xentria, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xentria, Inc.
What does Xentria, Inc. do?
Xentria is a biopharmaceutical company that develops biologic therapeutics for unmet clinical needs, with its lead asset XTMAB-16, an anti-TNF monoclonal antibody in clinical development for pulmonary sarcoidosis. The company also operates Xturnpoint, a venture studio with $100M in deployable capital that partners with academic researchers to advance early-stage therapeutic programs from preclinical through lead-optimization stages.
Is Xentria, Inc. a public or private company?
Xentria, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was Xentria, Inc. founded?
Xentria, Inc. was founded in 2020.
Where is Xentria, Inc. based?
Xentria, Inc. is headquartered in Chicago, United States, in the North America region.
How does Xentria, Inc. make money?
Three revenue lines are on record. Co-development partnerships and venture studio model is the primary driver. The others are licensing and development partnerships and biosimilar development.
Who are Xentria, Inc.'s main competitors?
Direct peers on record are PureTech Health, Roivant Sciences, aTyr Pharma, BridgeBio Pharma, Scholar Rock, Travere Therapeutics and Pliant Therapeutics. Broad incumbents are Janssen Pharmaceuticals, Amgen and AbbVie.
Does Xentria, Inc. have an API?
No public API is recorded for Xentria, Inc..
What industry is Xentria, Inc. in?
Xentria, Inc.'s product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 54169 and its SIC code is 2834.